Urogenital Infections and Inflammations

T.E. Bjerklund Johansen, F. M.E. Wagenlehner, Y.-H. Cho, T. Matsumoto, J. N. Krieger, D. Shoskes, K. Naber

Microbiology and resistance in urogenital tuberculosis

 Gernot Bonkat 1
N. M. Francisco 2
G. Müller 1
O. Braissant 1

1 alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB), University Basel, Basel, Switzerland
2 Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa


Mycobacteria are less common than other infections but still represent a significant threat to patients. Their slow growing nature and the late appearance of symptoms of urogenital mycobacterial infections often result in a delayed diagnostic and more severe consequences. UGTB is mostly linked to an active or inactive lung tuberculosis, as a consequence a similar immune response is expected. Unfortunately, compared to TB, very little is known on specific response to urinary tract infection caused by MOTT, still knowledge from BCG instillation for bladder cancer treatment suggest a similar process as well. With respect to treatment and drug resistance, considering the late onset of symptoms, the potentially large populations of mycobacteria in some lesion and their mutation rate, monotherapy should be avoided. Such monotherapy would mostly lead to the emergence of resistant subpopulations. In addition, some studies focusing on persisters emphasize that at least PZA and RIF should be included in the treatment regimen as those drugs have shown some activity on persisters.

Summary of recommendations

Although very little data exist with respect to the diagnostic and treatment of M. tuberculosis and other mycobacterial urogenital infections a few recommendations can be considered useful:

  • Because of the late appearance of some symptoms, patient showing repeated sterile pyuria or other symptoms (if any) should be screened for slow growing mycobacteria often missed in regular urine culture. Upon positive mycobacterial culture DST should be performed.
  • Considering the potentially high population in some lesion and the mutation rate for drug resistance, monotherapy should be avoided for M. tuberculosis and other mycobacterial urogenital infections.
  • As persisters are of major concern during the usually long treatment course of TB and MOTT infections, PZA and RIF should be included (if possible) in the regimen as those 2 drugs have shown some efficacy against such persisters.

1 A brief introduction to mycobacteria

Mycobacteria are slow growing microorganisms with generation time of a few hours to a few days on appropriate microbiological medium [1], [2]. They are conventionally divided in tuberculous mycobacteria and mycobacteria other than tuberculosis (MOTT). The first ones are mycobacteria able to cause tuberculosis (or leprosy) as the latter are mycobacteria unable to cause tuberculosis (even if they can cause other related lung disease). The diagnosis of mycobacteria is difficult because of their slow growing nature. Indeed mycobacteria are also divided based on their growth rate. The slow growing mycobacteria are expected to form a colony on Lowenstein-Jensen medium in more than 7 days (typically 10–28 [1]) as fast growing mycobacteria are expected to produce a colony in less than 7 days. Still a culture for diagnosis might take up to 61 days to become positive (positive MGIT sample, or colony appearing on Lowenstein Jensen medium) [3], [4], [5], [6]. Most mycobacteria except for those appearing to be obligate pathogens (M. tuberculosis, M. leprae) are commonly found in soils, dust and water bodies. In addition some MOTT such as M. smegmatis are common inhabitants of the genitourinary tract [1], [7], [8], [9]. Mycobacteria are responsible for a significant number of urinary tract and urogenital infections. Among mycobacterial infection, M. tuberculosis is the main pathogen encountered. However, other species of mycobacteria can represent up to 35% of isolates (Table 1). These mycobacteria are often not linked to an active or inactive lung TB.

Table 1: Mycobacteria other than tuberculosis isolates from genitourinary infections or urine samples (non exhaustive list) (Table based on references [4], [5], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21]).

M. abscessus M. avium intracellulare
M. gordonae M. bovis
M. fortuitum M. smegmatis*
M. kansasii M. phlei
M. marinum M. scrofulaceum
M. xenopi M. terrae
M. chelonae M. simiae
M. celatum M. haemophilum
M. gastrii M. xenopi
*Considered not pathogenic
†Rarely causes diseases

Urinary and urogenital mycobacterial infections are often diagnosed quite late as symptoms are usually not specific (see following sections/chapters) [22], [23]. Especially in urinary tuberculosis white blood cell count in urine is quite low compared to infection by MOTT [14]. This is also consistent with the physiology of mycobacteria in urine. Indeed mycobacteria have been shown to survive in human urine [19]. But, urine is a potent growth media for many microbes and mycobacteria can proliferate and thrive in it. Indeed mycobacteria have been shown to be able to growth in urine or in urine added with serum (growth conditions that mycobacteria could easily encounter in urinary tract, with or without lesions). Such growth took place at a slow rate [24] with doubling time as long as 99 hours. Indeed, a slow growth is consistent with the late appearance of symptoms as well. If several studies have focused on urinary tuberculosis, UTI caused by other mycobacteria have been much neglected in the last years, therefore very few data are available.

2 The case of urogenital tuberculosis (UGTB)

In terms of number, 10.4 million new cases of tuberculosis and 1.4 million fatalities were attributed to tuberculosis in 2015 [25]. In addition to the 1.4 million people killed by tuberculosis, 400,000 died due to co-infection with HIV [25], [26]. Data for Germany suggest that extrapulmonary tuberculosis (EPTB) represent ca 20.7% of cases of tuberculosis and among those cases 12% are UGTB (i.e., 2.5% of the total cases of TB). However, urinary tuberculosis is often linked to an active or inactive lung tuberculosis [14], [27] thus emphasizing that the primary entry route of infection are the lungs. On the contrary, but not surprisingly, urinary tract infections caused by other mycobacteria is not linked to active or inactive TB (diagnosed by chest X-ray [14]).

3 Immune response to urogenital tuberculosis (UGTB)

As UGTB is mostly linked to an active or inactive lung tuberculosis, one can expect that immune response is mostly similar. In tuberculosis immune response acts as follows: Following interaction between the pattern recognition receptors (PRRs) and M. tuberculosis ligands, the microorganisms are phagocytized by antigen presenting cells (APCs). Upon phagocytosis, APCs migrate to the draining lymph nodes, initiating T-cell mediated immunity by priming naïve T lymphocytes. T-cell mediated immunity develops after two to three weeks of infection [28], [29], [30]. The phagosome inside the cells interacts with secreted proteins and developed to an endosome. The endosome processes the mycobacteria and presents fragments to the major histocompatibility complex (MHC) class II, which in turn will present the peptides on the APC surface to the T cell receptor (TCR) of CD4+ T helper 1 cells. M. tuberculosis may also be killed by CD8+ T cells, whereby mycobacteria in the phagosome are processed by protease enzyme and transported to the endoplasmic reticulum (ER) by transporter associated with antigen processing (TAP). The peptide is thereafter loaded and transported to the Golgi apparatus, whereby it is presented by the MHC I to the TRC on the CD8+ T cells, which may exhibit cytotoxic effect against M. tuberculosis-infected cells [31], [32]. The CD8+ T lymphocyte cells can directly kill M. tuberculosis using granulysin [33], [34]. During APC- and T-cell interaction, various pro-inflammatory cytokines such as IL-6, IL-12, TNF and interferon-gamma (IFN-γ) are produced. These cytokines play a central role by inducing macrophage activation and inducible isoform of nitric oxide synthetase (iNOS) expression [35]. Also, they enhance surface expression of MHC class II molecules and increase secretion of inflammatory mediators. Besides APCs, CD4+ Th1 cells and CD8+ T cells, other immune cells such as B cells, NK cells, neutrophils and regulatory T cells accumulate at the infectious focus [33], [36], [37], [38]. Due to a high production of IL-12 by APC, the immune response is largely polarized towards a Th1 type. At the infection side, the effector Th1 cells undergo functional maturation [39] and increase their production of effector cytokines and chemokines. These two markers attract new immune cells, amplifying local inflammatory and promote the formation of granuloma. It is presumed that the formation of granuloma represents a host strategy to contain the M. tuberculosis infection and limit dissemination of pathogen. However, individuals with latent TB infection and active TB patients both develop granulomatous response.

Although a lot is known on the immune response to lung TB, very little (not to say anything) is known on specific response to urinary tract infection caused by M. tuberculosis or MOTT. Studies on the use of BCG instillation for bladder cancer suggest a similar process [40], [41]. Still some variations have been noted in the proinflammatory cytokine profile in active kidney tuberculosis patients [42].

4 The problem of antimycobacterial resistance

Due to their extremely thick and multi-layered hydrophobic cell wall, mycobacteria have an intrinsic resistance to some antibiotics that cannot penetrate such permeation barrier. In addition mycobacteria [43], [44] and in particular M. tuberculosis developed many ways to counteract the effect of drugs including efflux pumps, modified targets, as well as overexpression of the drug target. Also mycobacteria produce efficient beta lactamases and other drug inactivating enzymes [43], [44]. Moreover, rate of emergence of resistance to antimycobacterial can be quite high. For M. tuberculosis, mutation rate leading to resistance against rifampin, isoniazid, streptomycin and ethambutol are 3.32x10-9, 2.56x10-8, 2.29x10-8, and 1.0x10-7 (expressed in mutation/bacterium/cell division), respectively. With an approximate number of 108 mycobacteria per lesion, it appears that monotherapy will surely result in the appearance of resistance [44], [45], [46]. This situation can be observed in lung cavities but also in kidney cavities thus advocating for multiple drug therapy. Also less data are available, similar finding were made with MOTT with mutation rate ranging from 10-5 to 10-9. Among urinary tract pathogens M. fortuitum and M. avium were show to have the highest mutation rates for isoniazid and streptomycin, with 10-6 and 10-5 respectively [45]. Thus showing that such pathogens should also be considered carefully when initiating a treatment. This also emphasize that monotherapy should be avoided with MOTT as well in the context of urogenital infections with cavities containing large populations of mycobacteria.

From a more clinical point of view, delayed drug susceptibility results, inappropriate use of antimycobacterial compounds, interrupted treatment (due to drug shortage a state level, non compliance, or poor access from patient to drug caused by poverty), and presence of counterfeit drug lead to the appearance of these acquired resistance [44]. Further spread of the resistant strains combined with those bad practices lead to the appearance multiresistant TB strains. In 2015 MDR strains accounted for 4.6% of total TB cases (i.e., 480,000 case of MDR TB). Of these, 480,000 were primary infection/transmission of people having no previous TB history (i.e., likely transmission of an MDR strain). Only 21% (roughly 100,000) of these cases were found in individuals who received a successful TB treatments (i.e., likely acquired resistance link to previous drug treatment) [25], [47]. Finally it must be noted that within different countries the proportion of XDR TB within the MDR TB ranges from <1 to 11% (laboratory confirmed cases) and poses a major threat, especially considering that laboratory confirmed cases are probably highly underestimated [25]. As a result WHO considers that early initiation of appropriate drug treatment as well as avoiding transmission or acquisition of drug resistance is of critical importance [48].

5 Persistence in mycobacteria 

Persisters are usually defined as a genetically identical subpopulation that is non-replicating or slow-growing and can survive bactericidal antibotics. They have a uninheritable phenotypic resistance (or tolerance) to antibiotics, but they daughter cells remains fully susceptible [49]. Persistence in M. tuberculosis and other mycobacteria, seems can be induced by many different factors such as pH, oxygen concentration, starvation for example. Indeed, in the urinary tract the nutrient, pH and oxygen concentrations are factors which can vary a lot and that could induce persistence. Still recent research show that the traditional view of persisters being non-replicating or slow growing might be wrong. Furthermore, persistence when mycobacteria are exposed to INH might be driven by pulsing KatG expression that activates INH (that is a prodrug) in still dividing microorganisms (in this study M. smegmatis). Therefore low-frequency pulsing of KatG might be beneficial and promote persistent lineages of mycobacteria [50]. Still mechanisms for other drug might be very different [51] [52]. Overall this emphasize that persisters should be considered a threat and must be taken into account when choosing a drug regimen. Indeed, this suggest again that monotherapy should be avoided and that regimen should include at least PZA and RIF that are the two drugs which have shown some efficacy against persisters. To our knowledge no studies have been conducted to evaluated the role of persisters in urogenital infection by M. tuberculosis or other mycobacteria.

6 Conclusions

Many aspects of the biology and pathology of mycobacteria (tuberculosis but also MOTT) and their role in UGTB have not been studied in detail yet. As such gap in knowledge impairs optimal treatment and patient management further study in the field of UGTB is indispensable. Also considering their rising importance MOTT should also be better studied. Finally, mechanisms of persistence are also crucial and need to be understood as well.

7 Acknowledgement

O.B. work is currently supported by a grant from the Merian Iselin Stiftung (Basel, Switzerland).


[1] Cook GM, Berney M, Gebhard S, Heinemann M, Cox RA, Danilchanka O, Niederweis M. Physiology of mycobacteria. Adv Microb Physiol. 2009;55:81-182, 318-9. DOI: 10.1016/S0065-2911(09)05502-7
[2] Holt JG, Krieg NR, Sneath PHA, Staley JT, Williams ST. Bergey's manual® of determinative bacteriology. 9th ed. Baltimore: Williams & Wilkins; 1994.
[3] Hartmans S, de Bont JAM, Stackebrandt E. The Genus Mycobacterium--Nonmedical. In: The Prokaryotes. New York: Springer; 2006. p. 889–918. DOI: 10.1007/0-387-30743-5_33
[4] Chan DS, Choy MY, Wang S, Sng LH. An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). J Med Microbiol. 2008 Oct;57(Pt 10):1220-2. DOI: 10.1099/jmm.0.2008/001685-0
[5] Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004 May;42(5):2321-5. DOI: 10.1128/JCM.42.5.2321-2325.2004
[6] Becton Dickinson and Company. Bactec MGIT (Myco- bacteria growth indicator tube) supplemented with OADC enrichment and PANTA antibiotic mixture user guide. 2005. Available from: http://legacy.bd.com/ds/technicalCenter/inserts/L000180JAA(04).pdf
[7] Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol. 2009 Aug;107(2):356-67. DOI: 10.1111/j.1365-2672.2009.04161.x
[8] Falkinham JO 3rd. Growth in catheter biofilms and antibiotic resistance of Mycobacterium avium. J Med Microbiol. 2007 Feb;56(Pt 2):250-4. DOI: 10.1099/jmm.0.46935-0
[9] Petrini B. Non-tuberculous mycobacterial infections. Scand J Infect Dis. 2006;38(4):246-55. DOI: 10.1080/00365540500444652
[10] Chan TH, Ng KC, Ho A, Scheel O, Lai CKW, Leung R. Urinary tract infection caused by Mycobacterium terrae complex. Tubercle and Lung Disease. 1996 Dec;77(6):555–7. DOI: 10.1016/S0962-8479(96)90055-6
[11] Clark R, Cardona L, Valainis G, Hanna B. Genitourinary infections caused by mycobacteria other than mycobacterium tuberculosis. Tubercle. 1989 Dec;70(4):297–300. DOI: 10.1016/0041-3879(89)90025-1
[12] Dahl DM, Klein D, Morgentaler A. Penile mass caused by the newly described organism Mycobacterium Celatum. Urology. 1996 Feb;47(2):266–8. DOI: 10.1016/S0090-4295(99)80433-6
[13] Fox R, Mears J. Female genital tract Mycobacterium chelonae infection. J Obstet Gynaecol. 2004 Apr;24(3):326. DOI: 10.1080/01443610410001661084
[14] Huang CT, Chen CY, Chen HY, Chou CH, Ruan SY, Lai CC, Hsueh PR. Genitourinary infections caused by nontuberculous mycobacteria at a university hospital in Taiwan, 1996-2008. Clin Microbiol Infect. 2010 Oct;16(10):1585-90. DOI: 10.1111/j.1469-0691.2010.03180.x
[15] Indudhara R, Das K, Sharma M, Vaidyanathan S. Seminal vesiculitis due to Mycobacterium gastri leading to male infertility. Urol Int. 1991;46(1):99-100.
[16] Keller M, Mak A, Thibert L, Rene P, Klein MB. Mycobacterium haemophilum epididymal abscess in a renal transplant patient. J Clin Microbiol. 2008 Jul;46(7):2459-60. DOI: 10.1128/JCM.00735-08
[17] Macek P, Bodnarova M, Zavada J, Jezek P, Pavlik I, Slany M, Havelkova M, Stork J, Duskova J, Hanus T, Kocvara R. Mycobacterium marinum epididymoorchitis: case report and literature review. Urol Int. 2011;87(1):120-4. DOI: 10.1159/000328220
[18] Oatway WH Jr. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979 Dec;120(6):1389-90. DOI: 10.1164/arrd.1979.120.6.1389
[19] Orumwense PO, Torvinen E, Heinonen-Tanski H. The survival of mycobacteria in pure human urine. Water Sci Technol. 2013;67(8):1773-7. DOI: 10.2166/wst.2013.052
[20] Streit M, Böhlen LM, Hunziker T, Zimmerli S, Tscharner GG, Nievergelt H, Bodmer T, Braathen LR. Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol. 2006 Jan-Feb;16(1):79-83.
[21] Woods GL, Washington JA. Mycobacteria Other than Mycobacterium tuberculosis: Review of Microbiologic and Clinical Aspects. Clinical Infectious Diseases. 1987 Mar 1;9(2):275–94. DOI: 10.1093/clinids/9.2.275
[22] Wise GJ, Shteynshlyuger A. An update on lower urinary tract tuberculosis. Current Urology Reports. 2008 Jul;9(4):305–13. DOI: 10.1007/s11934-008-0053-9
[23] Zarrabi AD, Heyns CF. Clinical features of confirmed versus suspected urogenital tuberculosis in region with extremely high prevalence of pulmonary tuberculosis. Urology. 2009 Jul;74(1):41-5. DOI: 10.1016/j.urology.2008.12.083
[24] Bonkat G, Bachmann A, Solokhina A, Widmer AF, Frei R, Gasser TC, et al. Growth of Mycobacteria in Urine Determined by Isothermal Microcalorimetry: Implications for Urogenital Tuberculosis and Other Mycobacterial Infections. Urology. 2012 Nov;80(5):1163.e9-1163.e12. DOI: 10.1016/j.urology.2012.04.050
[25] World Health Organization. Global tuberculosis report 2016. 2016. Available from: apps.who.int/medicinedocs/en/d/Js23098en/
[26] Naber KG, Schaeffer AJ, Heyns CF, Matsumoto T, Shoskes DA, Bjerklund Johansen TE. Urogenital infections. Arnhem: European Association of Urology; 2010.
[27] Tonkin AK, Witten DM. Genitourinary tuberculosis. Seminars in Roentgenology. 1979 Oct;14(4):305–18. DOI: 10.1016/0037-198X(79)90027-0
[28] Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011;2011:405310. DOI: 10.1155/2011/405310
[29] Tsolaki AG. Innate Immune Recognition in Tuberculosis Infection. In: Advances in Experimental Medicine and Biology. Springer New York; 2009. p. 185–97. DOI: 10.1007/978-1-4419-0901-5_13
[30] van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002 Apr;15(2):294-309.
[31] Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009;27:393-422. DOI: 10.1146/annurev.immunol.021908.132703
[32] Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences. 1998 Jan 6;95(1):270–5. DOI: 10.1073/pnas.95.1.270
[33] Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol. 2009 Aug;21(4):378-84. DOI: 10.1016/j.coi.2009.06.004
[34] Grotzke JE, Lewinsohn DM. Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect. 2005 Apr;7(4):776-88. DOI: 10.1016/j.micinf.2005.03.001
[35] Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev. 2008 Dec;226:191-204. DOI: 10.1111/j.1600-065X.2008.00702.x
[36] Allie N, Grivennikov SI, Keeton R, Hsu NJ, Bourigault ML, Court N, Fremond C, Yeremeev V, Shebzukhov Y, Ryffel B, Nedospasov SA, Quesniaux VF, Jacobs M. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci Rep. 2013;3:1809. DOI: 10.1038/srep01809
[37] Francisco NM, Hsu NJ, Keeton R, Randall P, Sebesho B, Allie N, Govender D, Quesniaux V, Ryffel B, Kellaway L, Jacobs M. TNF-dependent regulation and activation of innate immune cells are essential for host protection against cerebral tuberculosis. J Neuroinflammation. 2015 Jun 26;12:125. DOI: 10.1186/s12974-015-0345-1
[38] Ulrichs T, Kosmiadi GA, Trusov V, Jörg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann SH. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol. 2004 Oct;204(2):217-28. DOI: 10.1002/path.1628
[39] Kapina MA, Shepelkova GS, Mischenko VV, Sayles P, Bogacheva P, Winslow G, Apt AS, Lyadova IV. CD27low CD4 T lymphocytes that accumulate in the mouse lungs during mycobacterial infection differentiate from CD27high precursors in situ, produce IFN-gamma, and protect the host against tuberculosis infection. J Immunol. 2007 Jan;178(2):976-85.
[40] Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007 Jul;61(6):299-305. DOI: 10.1016/j.biopha.2007.05.004
[41] Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res. 1998;26(3):155-9.
[42] Koziol-Montewka M, Kolodziejek A, Oles J, Janicka L. Proinflammatory cytokine profile in active kidney tuberculosis patients. Immunol Invest. 2004 Aug;33(3):277-85.
[43] Nguyen L, Pieters J. Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development. Annu Rev Pharmacol Toxicol. 2009;49:427-53. DOI: 10.1146/annurev-pharmtox-061008-103123
[44] Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet. 2013 Mar;29(3):160-9. DOI: 10.1016/j.tig.2012.11.005
[45] David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970 Nov;20(5):810-4.
[46] Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002 Feb;46(2):267-74.
[47] Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet. 2010 May;375(9728):1830–43. DOI: 10.1016/S0140-6736(10)60410-2
[48] Kulchavenya E. Best practice in the diagnosis and management of urogenital tuberculosis. Ther Adv Urol. 2013 Jun;5(3):143-51. DOI: 10.1177/1756287213476128
[49] Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother. 2012 May;56(5):2223-30. DOI: 10.1128/AAC.06288-11
[50] Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, McKinney JD. Dynamic persistence of antibiotic-stressed mycobacteria. Science. 2013 Jan;339(6115):91-5. DOI: 10.1126/science.1229858
[51] Dhar N, McKinney JD. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol. 2007 Feb;10(1):30-8. DOI: 10.1016/j.mib.2006.12.007
[52] Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis. 2004 Jan;84(1–2):29–44. DOI: 10.1016/j.tube.2003.08.003

The ZB MED – Information Center for Life Sciences, Germany, together with the European Association of Urology (EAU) provided the opportunity to publish a “Living Textbook” on “Urogenital Infections and Inflammations” in an open access form. This “Living Textbook” represents also an update of the Textbook on Urogenital Infections published 2010 by the International Consultation on Urological Infections and the EAU: http://www.icud.info/urogenitalinfections.html.

The “Living Textbook” will cover infections and inflammations of the kidney, the urinary tract, as well as the male and female genital tract considering pathogenesis, diagnostics, treatment, prophylaxis and future aspects. The “Living Textbook” will be structured into about 26 Sections each with two section co-chairs responsible for peer review of the chapters of each section. Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

The editors hope that this “Living Textbook” may become a useful instrument for physicians of different specialties taking care about patients suffering from these diseases.

Truls E. Bjerklund Johansen (Norway),

Florian ME Wagenlehner (Germany),

Yong-Hyun Cho (South Korea),

Tetsuro Matsumoto (Japan),

John N Krieger (USA),

Daniel Shoskes (USA),

Kurt G. Naber (Germany).

Publishing at PUBLISSO

Your chapter will be published at the PUBLISSO platform (https://books.publisso.de).

Information for corresponding authors

It is necessary for all corresponding authors to register at PUBLISSO.
To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

After registration, please complete your user profile. Information from your user profile will appear in the published chapter and the authors board of the book (http://books.publisso.de/publisso_gold/book/52). If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.
(If you do not want to be displayed in the authors board, but stay registered, you can disable this feature in your profile settings. In this case, your affiliation (publication data) will be displayed in the published chapter only.)

We kindly ask you to provide the co-authors email addresses in the manuscript so that we can contact them in case of queries.

Information for co-authors

After publication of your chapter, your affiliation (publication data) will be displayed in the published chapter.

If you also want to be displayed in the authors board of the book (http://books.publisso.de/publisso_gold/book/52), we kindly ask you to register at PUBLISSO. If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.

To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

If you do not want to be displayed in the authors board of the book, you do not have to register. Your affiliation (publication data) will be displayed in the published chapter only.


If you have any further questions please don’t hesitate to contact the PUBLISSO editorial office:

E-Mail: livingbooks@zbmed.de
Phone: +49 221 478-7093


The textbook will be structured in sections with two co-chairs each. Each section will start with an introductory chapter written by the two respective co-chairs presented like an editorial commentary in regard to the following chapters (see proposed contents of the book). The two co-chairs of each section will also peer review all chapters in their section and stimulate a consensus discussion within their section together with the authors and the main editors if needed.


Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.


Each manuscript should have up to approximately 3,000 words (excluding abstract, tables/figures and references). The abstract should count about 300 words.


The outline of each chapter should be structured as follows (similar as in the edition 2010, which can be downloaded for free: http://www.icud.info/urogenitalinfections.html):

  1. Abstract
  2. Summary of recommendations*/key notes*
    (*which ever term is more appropriate)
  3. Introduction
  4. Methods
  5. Results
  6. Further research
  7. Conclusions
  8. Acknowledgement
  9. Conflict of interest of each author
  10. References

Citation style

As a citation style, the Vancouver style is preferred.

Please mark your references in the text with square brackets ([1], [2], ...).

Summary of recommendations

We would like to have the Summary of recommendations at the beginning after the abstract (as in the edition 2010). However, we do not expect as in the edition 2010, that each recommendation is also specified according to Level of Evidence and Grade of Recommendation, because such a claim would not only need a systematic literature search (see below), but also a structured discussion in a defined group of experts.

Systematic literature search

A systematic literature search should be performed, at least of PUBMED/MEDLINE but ideally of several relevant databases in addition (like Cochrane CENTRAL) to find recent, high quality systematic reviews and/or primary research studies. It is not expected to perform for all chapters a de novo systematic review, if such reviews are already published recently, but it still may be indicated for some items. For questions relating therapy, it should be focused on evidence from (systematic reviews of) randomized controlled trials if available.

The method of the systematic literature search needs to be fully described in the section “Methods”, e.g.:

“A systematic literature search was performed for the last ... (usually 10) years in MEDLINE, Cochrane etc. with the following key words ... and the following limitations: e.g. UTI, age (adult?), ... clinical studies ... English ... abstract available ... only peer reviewed ...

A total of ... publications were identified, which were screened by title and abstract ... After exclusion of duplicates ... a total of ... were included into the review (analysis), supplemented by citations or known to the authors ... ”.

Clinical topics

Clinical topics should be focused on the importance to clinical practice according to the up to date scientific knowledge as presented in the literature. It should relate to questions/complaints/symptoms of patient/population concerning definition, diagnosis, therapy/prevention, intervention, and outcome in comparison, if different approaches are feasible. Please choose patient-important outcomes and focus on those, which you deem critical for decision-making.

Level of evidence and grade of recommendations

Any recommendation should be based on the level of evidence and the grade of recommendation. For this purpose the following system, modified from the Oxford Centre for Evidence-based Medicine should be used (EAU guidelines 2015):

Level of evidence (LE)

Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

Grade of Recommendations (GoR)

Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality

Comments (EAU guidelines 2015)

The aim of assigning a LE and grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation is not directly linear. Availability of randomized controlled trials may not necessarily translate into a grade “A” recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor – has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned.

Since the same rating system should be used in all chapters, for the sake of brevity the same sentence could be used in “Methods” for all manuscripts, because the rating system will be described in details in the Preface of the book:

“The studies were rated according to the level of evidence and the strength of recommendations graded according to a system used in the EAU guidelines modified from the Oxford Centre for Evidence-based Medicine [1].”


[1] European Association of Urology. Guidelines. Methodology section. 2015 ed. Arnhem: European Association of Urology; 2015. p. 3. ISBN/EAN: 978-90-79754-80-9. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf

The Living Handbook of Urogenital Infections and Inflammations is issued by:

European Association of Urology
att. Maurice Schlief, EAU executive manager business affairs

P.O.Box 30016
NL-6803 AA Arnhem, The Netherlands

Phone: 0031-26-38.90.680
E-mail: m.schlief@uroweb.org

Editor in Chief

responsible for the contents according to § 5 TMG and § 55 Abs. 2 RStV (Germany):

Kurt G. Naber, MD, PhD
Assoc. Professor of Urology

Technical University of Munich
Karl-Bickleder-Str. 44c
94315 Straubing, Germany

E-mail: kurt.naber@nabers.de

John N. Krieger MD, PhD

University of Washington Section of Urology


Daniel Shoskes MD, PhD

Cleveland Clinic Glickman Urological and Kidney Institute


Yong-Hyun Cho MD, PhD

St. Mary's Hospital, The Catholic University of Korea Department of Urology


Tetsuro Matsumoto MD, PhD

University of Occupational and Environmental Health Department of Urology


Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen Clinic of Urology and Andrology


Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital Urology Department


Kurt G. Naber MD, PhD

Technical University of Munich


Punit Bansal MD, PhD

R G Stone and Super Specialty Hospital
Department of Urology


Riccardo Bartoletti

University of Pisa
Department of Translational Research and New Technologies


Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital
Urology Department


PD Dr. med. Gernot Bonkat

University Basel
alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)


Prof. Tommaso Cai MD

Santa Chiara Regional Hospital
Dept. of Urology


Dr Leyland Chuang

Ng Teng Fong Hospital, National University Health System
Department of Medicine


Prof. Milan Cizman

University Medical Centre
Department of Infectious Diseases


Alison Crawford MSc

Queen's University
Department of Psychology


Pfofessor Svetlana Dubrovina MD, PhD

Rostov Medical State University
Obstetrics and Gynaecology


Dr Valerie Huei Li Gan MBBS (S'pore), MRCS (Edin), MMed (Surg), FAMS (Urology)

Singapore General Hospital
Department of Urology


Philip Hanno

University of Pennsylvania


Ass prof MD Gundela Holmdahl

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology


Udo B. Hoyme

HELIOS Hospital Erfurt Ltd.
Department of Gynecology and Obstetrics


David Hunstad

Washington University School of Medicine
Pediatrics / Molecular Microbiology


Gitte M. Hvistendahl

Aarhus University Hospital


Prof. Michael KOGAN M.D., PhD

Rostov State Medical University
Department of Urology


Dr Akihiro Kanematsu

Hyogo College of Medicine
Department of Urology


Frieder Keller

University Hospital Ulm
Department Internal Medicine 1, Nephrology


Professor Katarzyna Kilis-Pstrusinska PhD, MD

Wroclaw Medical University
Department of Pediatric Nephrology


MD, PhD Tae-Hyoung Kim

Chung-Ang University


John N. Krieger MD, PhD

University of Washington
Section of Urology


Prof Ekaterina Kulchavenya

Novosibirsk Research TB Institute, Novosibirsk State Medical University


Dr Christina Kåbjörn Gustafsson

Ryhov Hospital Jönköping


Dr. Bela Köves

South Pest Teaching Hospital
Department of Urology


Dr. med. Giuseppe Magistro

Ludwig-Maximilians-University of Munich
Department of Urology


Vittorio Magri

Urologic Clinic


András Magyar

South-Pest Hospital
Department of Urology


Professor Emeritus Brian Morris

University of Sydney
School of Medical Sciences


Baerbel Muendner-Hensen

ICA-Deutschland e.V.


Stephen F. Murphy

Feinberg School of Medicine, Northwestern University
Department of Urology


Kurt G. Naber MD, PhD

Technical University of Munich


Prof. Yulia Naboka

Rostov State Medical University
Department of Microbiology


Dr. J. Curtis Nickel MD

Queen's University
Department of Urology


Professor Ralph Peeker MD PhD

University of Gothenburg
Department of Urology


Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology


Prof. Gianpaolo Perletti M. Clin. Pharmacol.

University of Insubria
Department of Biotechnology and Life Sciences


Felice Petraglia

Department of Biomedical, Experimental and Clinical Sciences, University of Florence
Obstetrics and Gynecology


Michel Pontari

Temple University School of Medicine
Department of Urology


Dr. Jörgen Quaghebeur PhD. Med. Sci.

University Hospital Antwerp and University Antwerp
Department of Urology


Yazan F. Rawashdeh

Aarhus University Hospital
Paediatric Urology Section, Department of Urology


Professor Claus Riedl MD



Matthew Roberts

The University of Queensland
Faculty of Medicine


PD Dr. med Guido Schmiemann MPH

Institut für Public Health und Pflegeforschung, Universität Bremen
Abteilung Versorgungsforschung


Caroline Schneeberger MD PhD

Academic Medical Center (AMC)


Prof. Dr. med. Peter Schneede

Klinikum Memmingen
Department of Urology


Aaron C. Shoskes

Des Moines University Medical College of Ostheopathic Medicine


Daniel Shoskes MD, PhD

Cleveland Clinic
Glickman Urological and Kidney Institute


Prof. Dr. Roswitha Siener

University of Bonn
University Stone Centre, Department of Urology


Sofia Sjöström

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology


Mathew Sorensen

University of Washington School of Medicine
Department of Urology


Prof. Dr. Dr. Walter Ludwig Strohmaier FEBU

Regiomed-Klinikum Coburg. Medical School Regiomed
Urology and Paediatric Urology


Satoshi Takahashi

Sapporo Medical University School of Medicine
Department of Infection Control and Laboratory Medicine


Professor Paul Anantharajah Tambyah

Yong Loo Lin School of Medicine, National University Hospital
Department of Medicine


Peter Tenke

Jahn Ferenc South Pest Teaching Hospital
Department of Urology


Praveen Thumbikat

Department of Urology


Dr. Jose Tiran Saucedo

IMIGO / Universidad de Monterrey
Obstetrics and Gynaecology


Dominic Tran-Nguyen

Des Moines University


Dean Tripp

Queen's University
Psychology, Anesthesia & Urology



The Catholic University of Korea, St. Vincent's Hospital
Division of Infectious Diseases, Department of Internal Medicine


Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen
Clinic of Urology and Andrology


Assoc. Prof. Christian Wejse

Aarhus University, Aarhus University Hospital
Department of Infectious Diseases/Center for Global Health, Dept of Public Health


Prof. Dr. Mete Çek

Trakya University, School of Medicine